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Peter H. Byers
Good afternoon. I am Peter Byers, president of The
American Society of Human Genetics. Welcome to the
55th Annual Meeting of our Society. I extend a special
welcome to those of you who have taken time away
from rebuilding your lives, your homes, and your work-
places in New Orleans to join us at this wonderful meet-
ing, even in the face of such adversity.
Next year, for those from New Orleans, the trip to the
meeting will be a much shorter one. The directors of the
Society conferred with representatives from the Conven-
tion Bureau, and we are planning to have the meeting in
New Orleans in October. It is our conviction that this is
the right thing to do to help rebuild the city. All elements
of the meeting areas will be fully in operation by the end
of March 2006. The current planned date for the ASHG
meeting is October 10–14, 2006, but it may be moved
back 2 weeks to the 24th–28th to avoid overlap with the
Neurosciences meeting, which has moved to Atlanta for
the 14th–18th period. We will have an additional dis-
cussion at the business meeting that begins at 11:30 AM
on Friday, to provide you with details.
I would like to start with a story. I was in China
recently, with a dozen members of the Society, at the
Watson Center for Genomic Studies in Hangzhou. We
taught in a course on Genetics and Genomics in Medi-
cine. Our last ofﬁcial activity was an open genetics clinic
on Saturday morning, which, to raise interest, had been
discussed the day before in the regional newspapers and
television. We expected only a few visitors, but our ﬁve
teams were overwhelmed by more than 50 patients. Mar-
ilyn Li from Tulane and I shared a clinic room. Our last
patient was a 63-year-old man with mild hypertension,
looking forward to a long life. After telling us about his
conviction that beekeeping and ﬂowers in the bedroom
every day contributed to his and his wife’s good health,
he turned to me with a twinkle in his eye and said—
through Marilyn—that he had enjoyed the visit and
thought that, if only we spoke the same language, we
would have so much to discuss. This simple statement
mirrors our profession. If you look to your left and to
your right, you will probably see people with whom you
have never spoken and who are from a different part of
our ﬁeld. If only we spoke the same language.
Human genetics is a complex and diversiﬁed ﬁeld.
Clinicians, investigators who deal with human subjects
(and who may themselves be clinicians), statistical ge-
neticists, genetic epidemiologists, subjects, advocacy or-
ganizations, the families themselves, industry, research
institutions, funding agencies, and others constitute our
ﬁeld. We all see the world of genetics differently—we
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see different threats, we see different opportunities, and
we speak of those in different languages.
I would like to take the new few minutes to talk about
three areas in which we, as individuals and as a Society,
can breach those language and conceptual barriers to
make differences—ﬁrst, ways to bolster education in sci-
ence and genetics, from the primary level through doc-
toral and post-doctoral levels in medicine and other ﬁelds;
second, the alleviation of the growing concerns with hu-
man research, access of subjects to programs and of in-
vestigators to subjects; and third, identiﬁcation of means
to assure that the commercialization of genetic testing
does not fragment training and access to important clin-
ical data.
Education in Science and Why
Our perception of the strength and success of human
genetics as a discipline and of the contributions this dis-
cipline makes to better our understanding of us as peo-
ples and to the betterment of our lot are not viewed by
all through the warm lens that we use. To me, it is the
failure of others to understand the thrill of the ﬁeld and
the promises that we think it brings that is so puzzling.
Genetics seems, on its face, quite simple. Think about
the alphabet of genetics—the four letters A, C, G, and
T. Innocuous. Howmany words can you spell with these
three consonants and one vowel? Not SEX, not GOD,
not RELIGION, not POLITICS—all hot-button topics—
not even WEATHER. And yet, genetics brings fear of
discrimination based on genetic characteristics, is a threat
because of the relationship of genetics to evolution, and
these fears stand in the way of unraveling the role of
genetics in medicine and the promises that genetics brings.
We need to be better at explaining genetics and its
value to our public. We have a few great communicators
in our midst, but most of us are uneasy in public, have
not quite ﬁgured out how to get our points across, and
shrink from the opportunities when they arise. We are
not good advocates and don’t speak the public language
well. Perhaps we can start in schools.
As a Society, we have discussed ways to become en-
gaged in science and genetics education for years, as an
organization and through our members. We have es-
tablished a mentor network that allows teachers around
the country to contact nearby geneticists who are willing
to come to the classroom, to supervise students in the
laboratory if they are far enough along, and to serve as
resources for those teachers. Although wonderful in con-
cept, the execution of this tool has not always been suc-
cessful. Many of us, unless we have struggled with our
children’s biology and chemistry textbooks in high school
or helped with the ubiquitous terrarium designs in mid-
dle school, have little concept of what a student at any
given level, from ﬁrst grade through high school, knows
about genetics, what the teaching expectations are for
that grade level, or how to engage students.
Little wonder that we are, no matter our academic sta-
tion, seldom called to help and, if called, rarely recalled.
We are now in the midst of a project that has the
potential to change the orientation of our members to
school science, a project Bob Nussbaum mentioned last
year. In cooperation with our sister group, the Genetics
Society of America, we (the “we” in this case being
Kenna Shaw, who is not here today because she has just
delivered the full sequence of her own ﬁrst human ge-
nome project and is trying to ﬁgure out her son’s in-
struction manual) have assembled the learning objec-
tives, for all grades (1–12) in all 50 states, for biology
as related to genetics. This is a phenomenal task that is
nearing completion and will soon be accessible at our
Society Web site so that, when you are invited to help,
you can identify the curricular needs with the teacher
and contribute your own expertise to meeting those
learning objectives. This will remove some of the anxiety
about what to talk about and how it relates to the cur-
riculum the teacher is required to get through.
Susanne Haga, co-chair of our Information and Ed-
ucation Committee (who hosted a magniﬁcent program
for high school students from the region at this year’s
meeting), and Joe McInerney, our Excellence in Educa-
tion awardee this year, have pointed out that learning
in genetics need not be limited to our traditional biology
courses. They do see the vertical nature of teaching with
progressive involvement in biology and evolution during
the transition from preschool or elementary school to
high school, but also the horizontal scope of genetics as
examples in mathematics classes (recurrence risks, for
example), in history classes (the distribution of popula-
tions), in psychology and sociology classes (genetics and
behavior), to name only a few. For us as professionals,
genetics is a pervasive explanatory tool for the phenom-
ena of the biological and social worlds around us. Teach-
ing in schools provides opportunities to introduce these
ideas to teachers and students and to transmit to them
the wonder that we all discovered with mentors famous
and known to us all—Barton Childs, Arno Motulsky,
Victor McKusick, Charles Scriver, Jim Neel, James Crow
(and you can name your own)—or those private men-
tors—like Lester Newman at Portland State College in
Oregon, with whom I clambered up the streams on Mt.
Hood looking for ﬂy larvae from which to make chro-
mosome preps back in the lab—and whose guiding lights
still lead us.
Education in science has always been important to us
as citizens, but, with rapid technological changes, the
evolution in the economies of developed countries, and
a rapidly changing social world, it is more vital than
ever. Science teachers are a commodity in short supply
in schools, and, as a consequence, the sciences as dis-
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ciplines appear to suffer. All of you who have children
know that they are natural scientists—until they go to
school. They have “Insatiable Curiosity” and want and
develop explanations for everything around them. They
are busy testing hypotheses about the world, never stop-
ping to think that they are scientists. Until they go to
school. Once in school, “science” becomes a “body of
knowledge” encapsulated in the courses on biology,
earth sciences, chemistry, and physics, and students lose
interest.
Mort Levine, an anthropologist who taught at Reed
College when I was there, said that many students come
to college thinking they will major in science because it
is a body of known materials that can be captured. They
change disciplines when they discover that science is de-
voted to asking questions about what is not known.
Thus, the exodus into business, law, literature, and the
humanities, where known rules explain behaviors (or so
they think). For us, as scientists, as geneticists, it is the
ability to ask questions about what we don’t know and
be thrilled by the answers because we have crossed a
new boundary into what is now known. I remember the
sheer joy I experienced when I looked at the electro-
phoresis gel of proteins from a patient with a severe form
of osteogenesis imperfecta (OI) and saw that the over-
modiﬁcation of the proteins had to be explained by a
single nucleotide substitution that changed a glycine in
the triple helix. There were 338 glycines in the triple he-
lical portion and 8 potential amino acid substitutions—
think of the possibilities—nowonder the clinical features
of OI are so heterogeneous. And there were two genes.
It took another year or so before Dan Cohn showed this
was the case, but, by then, we knew that OI was a
protein-folding disease and that aberrant folding was
probably the underlying basis of most genetic disease.
I remember our discovery—or recognition—that re-
currence of lethal OI in a family was explained by pa-
rental mosaicism. We could see it from family struc-
ture—the parent that had affected children by two dif-
ferent mates. Once we had the right family—a mosaic
father (found for us by Bruce Blumberg)—we could look
in sperm and other tissues and conﬁrm our idea and
then recognized that we had a tool by which we could,
perhaps, count the number of primordial germ cells al-
located to the germ line. I am sure that every one of you
in this audience has had that elation of discovery—of
retrieving something from the unknown. That is what
we want to teach our students about—how to ﬁnd an-
swers to questions in a way that brings that thrill.
That is the beauty of being in science.
I look forward to the day when a president of the U.S.
is well enough educated in science and genetics, and cu-
rious enough, to recognize that “teach the controversy”
has nomeaning.We need to teach the language of science
so that we can all speak it.
Our educational efforts should not stop with formal
schooling. Because they control the purse strings, our
legislators hold the future of science, of genetics, and of
science education in their hands. For most of us, neither
our education in science or medicine nor our inclinations
move us to work with public ofﬁcials. If we look at the
likely effects of the ﬂat or declining funding for the NIH
and the NSF in this country, we can predict that some
of the hardest hits will come to the institutions and fac-
ulty that are just starting up the research ladder.We need
to educate our legislators, our school boards, and our
teachers and staff about the value of science to our
communities.
Invite your legislators, your public ofﬁcials, or their
staff to lunch, to the lab; show them what you do—or
simply go visit them. In turn, learn their language and
limitations and work with them to search for ways that
science education, indeed education as a whole, remains
a priority. When enough of us speak the same language
or our abilities to translate have improved, we will, in-
deed, have more to discuss.
The best advocates for human genetics and for re-
search and teaching have been the families that have
harbored the genetic disorders we study. The families
and organizations they spawned have led the search for
research dollars, brought effective legislation to states
and the federal government that could limit deleterious
effects from genetic testing, and convinced a sometimes-
skeptical public that genetic studies will be beneﬁcial,
not harmful. Their help in keeping access to identiﬁed
disease-related genes open should neither be underesti-
mated nor ignored. Instead, this represents a new part-
nership among scientists, clinicians, and families. It is
our turn as professionals to take up the banners of advo-
cacy at all levels. As a start, we can work for the passage
of the Genetic Non-Discrimination Act in the House of
Representatives, to reduce the anxiety about genetic test-
ing in the clinical setting. It is part of our responsibility
to use the newly minted coinage of the human genome
for the beneﬁt of all.
Many of the family advocacy groups have joined our
Society, used our extended home to engage our profes-
sional members while at this meeting and to create dy-
namic working relationships that pressed critical research
issues and solved clinical and social problems. This year,
we have provided access to our entire meeting to advo-
cacy groups that have never had the experience, and we
are helping them through the maze of new information.
I welcome them and hope they will enjoy the meeting.
We have worked to get our trainees involved with the
family groups. To watch the relationships develop be-
tween the members of these lay organizations and the
members of our Society, particularly the young students
and fellows, is to see the wonder of the human spirit
meeting the marvel of science and genetics in action. To
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watch the black humor of science and medicine trans-
formed by this relationship into the white heat of com-
mitment and advocacy is to see everything we have hoped
for in forming and continuing this Society. Here, we have
seen the way to learn these different languages we speak.
Institutional Review Boards and Research in Human
and Medical Genetics
In the practice of medicine, an overriding concept has
been “above all, do no harm” (primum non nocere),
attributed both to Hippocrates (The Epidemics: “…at
least do no harm”) and to Galen. This concept has been
institutionalized in the framework of research that in-
volves humans in the Nuremburg Code, the elements of
the Belmont Report, and detailed in the U.S. codes that
govern these activities and out of which institutional
review boards (IRBs) have grown. Now, every institution
that conducts federally funded research has panels that
review applications to do research that involves human
subjects. “Involves” may be a key component. The task
set before these panels was to be sure that subjects were
informed of the studies to be done, to exclude coercion
as a reason for participation, and to assess the potential
for harm to the subject.
The statements of principle set out in the Nuremburg
Code and the Belmont Report are elegant in their sim-
plicity and objectives. During the last few decades, we
have seen the application of these principles engender
increasingly complex formulas that have cast investiga-
tors, potential subjects, the IRBs, the institutions, advo-
cacy groups, and funding agencies in potential, and
sometimes real, adversarial relationships.
Federal regulations appropriately require that IRBs not
be monolithic in makeup but broadly represent the in-
terests of the society. From the perspective of the genetics
community, the application process has become increas-
ingly burdensome as “genetics” has been singled out for
special treatment. The University ofWashington Human
Subjects Division Web site illustrates this point:
In response to increasing national concern about
genetic testing and other genetic studies, theUniversity
of Washington Human Subjects Committees are now
examining all studies which involve genetics with in-
creased scrutiny. While genetic studies often involve
minimal physical risk, they do carry signiﬁcant psy-
chological and social risks. Genetic information car-
ries with it risks to insurability, risks to family life (for
example, in incidentally generated information about
paternity), and risks to life plans (for example, from
discovery of previously unknown but possibly stig-
matizing conditions).
Thus, while we as geneticists have tried to eliminate
the idea of “genetic exceptionalism,” we now ﬁnd the
concept institutionalized without validating data. The
ethicist, who used to be descriptive, has become pre-
scriptive, viewing the situation from the bottom of the
slippery slope.
As the need for large cohorts gathered from multiple
sites increases, the problems of dealing withmultiple and
independent IRBs at many institutions has become an
industry in itself. We ﬁnd ourselves unable to speak the
same language.
This is the time for the advocacy groups to step in,
to work with investigators and IRB staffs and members,
to clarify what, for them, are the real issues, and to craft
novel and creative solutions to the impasses that we see
and feel. The advocacy groups have been adept at learn-
ing the language of disparate groups and providing trans-
lation and guidance in other situations. Let’s see if it
works here. If it doesn’t, we are in for a long haul.
Commercialization of Genetic Testing and Loss
of Genotype Data and Training Sites
I would like to turn to one ﬁnal topic—the effects of
moving genetic testing out of the academic medical cen-
ters to commercial sites. There are three elements that
concern me—the separation of genotype information
now located in the testing sites from the phenotype data
stored at disparate institutions, the loss of academic
training sites for molecular geneticists, and the culling
of the only ﬁnancially stable component of medical ge-
netics. These latter two have been a favorite issue of
Aubrey Milunsky for years—ones he has articulated well.
While I think the technical quality of testing in most
commercial sites is very good, the interpretation of the
studies may leave something to be desired. But, more
importantly, the clinical information collected is often
limited and, because the expertise in the clinical con-
ditions is separated from the testing, the opportunity to
interpret the effects of the mutations—that is, to perform
coherent genotype/phenotype analyses—is being lost. The
solution to this problem is not clear. But efforts to follow
best-practice recommendations in terms of licensing of
use and a commitment from testing laboratories tomain-
tain a continued relationship with test or gene origina-
tors, so that clinical data accumulation continues and
genotype-phenotype relationships are determined, should
all be pursued. Advocacy groups can and should inter-
vene in the process because, in the long run, it is their
members who have much to lose.
A Personal Statement
I have—and I think many, if not most, of you think you
have—the best job in medicine. I am a clinician by train-
ing and an investigator by temperament. At any given
moment, my job involves me with a patient; his or her
family; the nucleotides gone astray that cause their dis-
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orders; treatments at the gene or physiological level; a
consideration of what we know, how we know it, and
what we don’t know; with the role of genetics in society;
teaching students and fellows; and trying to understand
how to integrate genetics as a medical discipline within
our university structure. Mine is a job I have trouble
imagining differently, one that fulﬁlls most of the hopes
and aspirations that I have, and one that occupies me
throughout the day. I am never not a geneticist. This
Society has made a home for me, and I am deeply grate-
ful to it.
Our Society is robust today, with a strong ﬁnancial
position and an energetic role in science and social pol-
icy—something only imagined less than a decade ago.
We have created a family of genetic organizations from
our nest—The American Board ofMedical Genetics, The
American College of Medical Genetics, The American
Society of Genetic Counselors, The American Board of
Genetic Counseling, The Society for Gene Therapy, The
Society for Metabolic Disorders, the Human Genome
Organization, The Society for Human Variation, the In-
ternational Societies of Human Genetics. Under our roof,
many other organizations have developed, including some
of the very strong advocacy groups—the National Or-
ganization of Rare Disorders, The Genetic Alliance—that
ﬂourished under our wings, if not always our guidance.
Last Remarks
As we begin our 56th year, we are like parents whose
children are out of the house and launched in successful
careers, perhaps writing books about genetics and so-
ciety like my own son, Michael. We have immeasurable
pride in their accomplishments, recognizing what little
we have done besides providing the safe harbor for their
development. We measure our strength by our offspring
and the ability to produce them. As a Society, as our
“children” have left home, it is not that we are once
again enjoying sex with noise, but that we are looking
to the appearance of a new generation of genetic orga-
nizations and relationships—the genetic grandchildren
of the Society.
It is my profound hope that, as they arrive, we will
have common tongues—the languages of science, of ge-
netics, of humanity, and a shared vision and hope for
the future—ones that we will share with our constitu-
encies, our colleagues, and our advocates.
